Evidence map›Paper›PMID 38757077›Full record

ReviewInternational journal of particle therapy2024

PTCOG Gastrointestinal Subcommittee Lower Gastrointestinal Tract Malignancies Consensus Statement.

J Isabelle Choi, Andrzej Wojcieszynski, Richard A Amos, Huan Giap, Smith Apisarnthanarax, Jonathan B Ashman, Aman Anand, Luis A Perles, Tyler Williamson, Shanmugasundaram Ramkumar and 3 more

Abstract readReview
In one paragraph

Review in International journal of particle therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Towards proton therapy guidelines for radiation therapists and dosimetrists: A scoping review.Technical innovations & patient support in radiation oncology · 2025
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

J Isabelle ChoiDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Andrzej WojcieszynskiKaiser Permanente, Denver, Colorado, USA.
Richard A AmosDepartment of Medical Physics & Biomedical Engineering, University College London, London, UK.
Huan GiapMedical University of South Carolina, Charleston, South Carolina, USA.
Smith ApisarnthanaraxDepartment of Radiation Oncology, University of Washington, Seattle, Washington, USA.
Jonathan B AshmanDepartment of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona, USA.
Aman AnandDepartment of Radiation Oncology, Mayo Clinic, Scottsdale, Arizona, USA.
Luis A PerlesDepartment of Radiation Physics, UT MD Anderson Cancer Center, Houston, Texas, USA.
Tyler WilliamsonDepartment of Radiation Physics, UT MD Anderson Cancer Center, Houston, Texas, USA.
Shanmugasundaram RamkumarProton Therapy UK, Prague, CZ.
Jason MolitorisDepartment of Radiation Oncology, University of Maryland Medical Center, Baltimore, Maryland, USA.
Charles B SimoneDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Michael D ChuongDepartment of Radiation Oncology, Miami Cancer Institute, Miami, Florida, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Radiotherapy delivery in the definitive management of lower gastrointestinal (LGI) tract malignancies is associated with substantial risk of acute and late gastrointestinal (GI), genitourinary, dermatologic, and hematologic toxicities. Advanced radiation therapy techniques such as proton beam therapy (PBT) offer optimal dosimetric sparing of critical organs at risk, achieving a more favorable therapeutic ratio compared with photon therapy. Materials and Methods: The international Particle Therapy Cooperative Group GI Subcommittee conducted a systematic literature review, from which consensus recommendations were developed on the application of PBT for LGI malignancies. Results: Eleven recommendations on clinical indications for which PBT should be considered are presented with supporting literature, and each recommendation was assessed for level of evidence and strength of recommendation. Detailed technical guidelines pertaining to simulation, treatment planning and delivery, and image guidance are also provided. Conclusion: PBT may be of significant value in select patients with LGI malignancies. Additional clinical data are needed to further elucidate the potential benefits of PBT for patients with anal cancer and rectal cancer.

Indexed as

Anal cancerProton therapyQuality of lifeRectal cancerToxicity

Identifiers

PMID38757077
PMCPMC11095104

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.